Coloplast reported strong Q2 20 numbers. Sales (driven by chronic care) rose 9% on an organic basis, with the EBIT margin at 32% (+1pp due to operating leverage and cost-cutting). The company announced a dividend of DKK5/share and re-iterated FY20 expectations (4-6% topline growth, 30-31% EBIT margin). Capex will be increased to DKK950m (vs DKK 850m earlier), in order to boost production. In anticipation of unwinding stockpiling effects, we do not expect any significant changes to our estimat
11 May 2020
Q2 20: COVID-19 tailwinds lift chronic care
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q2 20: COVID-19 tailwinds lift chronic care
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
11 May 2020 -
Author:
Virendra Chauhan -
Pages:
3
Coloplast reported strong Q2 20 numbers. Sales (driven by chronic care) rose 9% on an organic basis, with the EBIT margin at 32% (+1pp due to operating leverage and cost-cutting). The company announced a dividend of DKK5/share and re-iterated FY20 expectations (4-6% topline growth, 30-31% EBIT margin). Capex will be increased to DKK950m (vs DKK 850m earlier), in order to boost production. In anticipation of unwinding stockpiling effects, we do not expect any significant changes to our estimat